Diamyd Medical develops precision medicine therapies for the prevention and treatment of Type 1 diabetes and LADA (latent autoimmune diabetes in adults).
Diamyd is an antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production. It has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation.
DIAGNODE-3, a confirmatory phase 3 trial, uses injections into a superficial lymph node can to optimize the treatment response.
This week on the podcast we have a conversation about treatments of type 1 diabetes, including the company’s development of Diamyd. Our guest is Anders Essen-Möller, founder and chairman of Diamyd Medical.
00:51-19:16: Diamyd Medical’s approach to Type 1 diabetes
19:16-21:03: Other approaches to tackling Type 1 diabetes
21:03-22:08: Keeping costs of Type 1 diabetes treatment low
22:08-22:53: Can Type 1 diabetes be cured?
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
Diamyd Medical develops precision medicine therapies for the prevention and treatment of Type 1 diabetes and LADA (latent autoimmune diabetes in adults).
Diamyd is an antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production. It has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation.
DIAGNODE-3, a confirmatory phase 3 trial, uses injections into a superficial lymph node can to optimize the treatment response.
This week on the podcast we have a conversation about treatments of type 1 diabetes, including the company’s development of Diamyd. Our guest is Anders Essen-Möller, founder and chairman of Diamyd Medical.
00:51-19:16: Diamyd Medical’s approach to Type 1 diabetes
19:16-21:03: Other approaches to tackling Type 1 diabetes
21:03-22:08: Keeping costs of Type 1 diabetes treatment low
22:08-22:53: Can Type 1 diabetes be cured?
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter